Format

Send to

Choose Destination
Oncotarget. 2017 May 16;8(20):33897-33910. doi: 10.18632/oncotarget.15406.

Immunotherapeutic approaches for hepatocellular carcinoma.

Author information

1
Medical Oncology Unit, Hospital of Taranto, Taranto, Italy.
2
Medical Oncology Unit, Hospital of Gallipoli, Gallipoli, Italy.
3
Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori IRCCS, Meldola, FC, Italy.
4
Department of Medical Oncology, University of Cagliari, Cagliari, Monserrato, CA, Italy.
5
Department of Hepatobiliary Surgery, Ospedale Regionale "F.Miulli", Bari, Italy.
6
Department of Biomedical Sciences and Human Oncology, Clinica Medica "A. Murri", University of Bari Medical School, Bari, Italy.
7
Department of Oncology, San Bortolo Hospital ULSS 6, Vicenza, Italy.
8
Medical Oncology Unit, University Campus Biomedico, Rome, Italy.
9
Pharmacy Unit, National Cancer Research Centre, Istituto Tumori Giovanni Paolo II, Bari, Italy.
10
Medical Oncology Unit, National Cancer Research Centre, Istituto Tumori Giovanni Paolo II, Bari, Italy.

Abstract

Hepatocellular carcinoma (HCC) is a cancer with a high mortality rate due to the fact that the diagnosis usually occurs at anadvanced stage. Even in case of curative surgical treatment, recurrence is common. Sorafenib and regorafenib are the only therapeutic agents that have been demonstrated to be effective in advanced HCC, thus novel curative approaches are urgently needed. Recent studies focus on the role of immune system in HCC. In fact, the unique immune response in the liver favors tolerance, which can represent a real challenge for conventional immunotherapy in these patients. Spontaneous immune responses against tumor antigens have been detected, and new immune therapies are under investigation: dendritic cell vaccination, immune-modulator strategy, and immune checkpoint inhibition. In recent years different clinical trials examining the use of immunotherapy to treat HCC have been conducted with initial promising results. This review article will summarize the literature data concerning the potential immunotherapeutic approaches in HCC patients.

KEYWORDS:

adoptive immunotherapy; dendritic cell vaccination; hepatocellular carcinoma; immune checkpoint; immunotherapy

PMID:
28420805
PMCID:
PMC5464921
DOI:
10.18632/oncotarget.15406
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Impact Journals, LLC Icon for PubMed Central
Loading ...
Support Center